On December 23, 2024, Viatris disclosed that "following an inspection by the U.S. FDA" at the Company's manufacturing facility in Indore "the Agency has issued a Warning Letter, and an Import Alert related to this facility" which "affects 11 actively distributed products that will no longer be accepted into the U.S. until the Warning Letter is lifted."